This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights Merrimack Pharmaceuticals, Moderna and Seagen
by Zacks Equity Research
Highlights Merrimack Pharmaceuticals, Moderna and Seagen are included in this Analyst Blog.
Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More
by Zacks Equity Research
Pipeline updates from MACK and MRNA are the key highlights from the biotech sector during the past week.
Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Merrimack's (MACK) loss betters estimates in Q4. However, the company fails to earn any revenues in the period.
Merrimack (MACK) Stock Up Year to Date: Is a Rebound Likely?
by Zacks Equity Research
Merrimack (MACK) regains its status as a development-stage biopharma company after the sale of its sole marketed product Onivyde in 2017.
Merrimack (MACK) Down 7.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Merrimack (MACK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3
by Zacks Equity Research
Merrimack (MACK) discourages with Q3 loss, falling shy of estimates as well as deteriorates from the year-ago quarter's figure. Also, the company fails to reap any revenues in the period.
5 Drug/Biotech Stocks Set to Trump Estimates in Q3 Earnings
by Zacks Equity Research
There are still a number of drug/biotech companies poised to surpass third-quarter estimates.
Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod
by Zacks Equity Research
Earnings releases and key data-read outs were the key developments in the biotech sector last week.
Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts
by Zacks Equity Research
Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.
Merrimack (MACK) Up 6.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Merrimack (MACK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com highlights: American Woodmark, Adverum Biotechnologies, Merrimack Pharmaceuticals, Athene Holding and M&T Bank
by Zacks Equity Research
Zacks.com highlights: American Woodmark, Adverum Biotechnologies, Merrimack Pharmaceuticals, Athene Holding and M&T Bank
Move Beyond Bargain Hunting: 5 Stocks With Rising P/E
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q2
by Zacks Equity Research
Merrimack's (MACK) loss is wider than expected in Q2 but narrower than the year-ago quarter's deficit. Meanwhile, the company did not generate any revenues in the reported quarter.
Merrimack (MACK) Reports Wider-than-Expected Q2 Loss
by Zacks Equity Research
Merrimack Pharmaceuticals (MACK) reports wider-than-expected loss in Q2. The company did not record any revenues in the quarter.
Is a Beat in the Cards for Merrimack (MACK) in Q2 Earnings?
by Zacks Equity Research
On Merrimack's (MACK) second-quarter 2018 conference call, investor focus will be on the company's progress with pipeline candidates.
Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod
by Zacks Equity Research
The biotech sector was in the news with a few hits and misses. Gilead's Biktarvy got approval in Europe while Puma Biotechology is also closer to breast cancer drug approval in Europe.
Merrimack Crashes as Phase II Pancreatic Cancer Study Fails
by Zacks Equity Research
Merrimack (MACK) plunges, following the announcement of failure of the CARRIE phase II study on pipeline candidate, MM-141, for the treatment of metastatic pancreatic cancer.
Options Traders Expect Huge Moves in Merrimack Pharmaceuticals (MACK) Stock
by Zacks Equity Research
Investors in Merrimack Pharmaceuticals (MACK) need to pay close attention to the stock based on moves in the options market lately.
Why is Merrimack (MACK) Up 6.3% Since Its Last Earnings Report?
by Zacks Equity Research
Merrimack (MACK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1
by Zacks Equity Research
Merrimack (MACK) reports wider-than-expected loss in the first quarter.
Merrimack (MACK) Reports Wider-than-Expected Q1 Loss
by Zacks Equity Research
Merrimack posted wider-than-expected loss in the first quarter of 2018. The company reported no revenues during the period.
What's in the Cards for Merrimack (MACK) in Q1 Earnings?
by Zacks Equity Research
Investor focus is likely to remain on Merrimack's (MACK) pipeline updates when it reports first-quarter numbers.
Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Merrimack (MACK) reports narrower-than-expected loss in the fourth quarter due to lower operating expenses.
What's in the Cards for Merrimack (MACK) in Q4 Earnings?
by Zacks Equity Research
Investors are likely to remain focused on Merrimack's (MACK) pipeline updates when it reports Q4 numbers, early next month.
Merrimack (MACK) Down 7.8% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Merrimack (MACK) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.